InspireMD (NSPR) 10-K 28 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Mar. 28, 2016	Jun. 30, 2015
Document And Entity Information
Entity Registrant Name	InspireMD, Inc.
Entity Central Index Key	1,433,607
Document Type	10-K
Trading Symbol	NSPR
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 19,428,337
Entity Common Stock, Shares Outstanding		10,726,841
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
CURRENT ASSETS:
Cash and cash equivalents	$ 3,257	$ 6,300
Accounts receivable:
Trade, net	405	635
Other	142	359
Prepaid expenses	75	150
Inventory	753	1,924
Total current assets	4,632	9,368
NON-CURRENT ASSETS:
PROPERTY, PLANT AND EQUIPMENT, net	472	622
Deferred issuance costs	85	153
Fund in respect of employee rights upon retirement	502	498
Long-term prepaid expenses		66
Royalties buyout	87	752
Total non-current assets	1,146	2,091
Total assets	5,778	11,459
Accounts payable and accruals:
Trade	512	909
Other	2,006	3,576
Advanced payment from customers	167	179
Current maturity of loan	4,234	3,809
Total current liabilities	6,919	8,473
LONG-TERM LIABILITIES:
Liability for employees rights upon retirement	706	687
Long-term loan	1,099	5,086
Total long-term liabilities	$ 1,805	$ 5,773
COMMITMENTS AND CONTINGENT LIABILITIES (Note 9)
Total liabilities	$ 8,724	$ 14,246
EQUITY (CAPITAL DEFICIENCY):
Common stock, par value $0.0001 per share; 50,000,000 shares authorized; 7,676,074 and 4,136,852, shares issued and outstanding at December 31, 2015 and 2014, respectively	1
Additional paid-in capital	120,049	104,624
Accumulated deficit	(122,996)	(107,411)
Total capital deficiency	(2,946)	(2,787)
Total liabilities net of capital deficiency	$ 5,778	$ 11,459

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2015	Oct. 01, 2015	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001		$ 0.0001	$ 0.0001
Common stock, authorized	50,000,000	50,000	125,000	50,000,000
Common stock, issued	7,676,074	7,800	78,000	4,136,852
Common stock, outstanding	7,676,074	7,800	78,000	4,136,852

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
REVENUES	$ 2,310	$ 2,818
COST OF REVENUES	2,606	2,034
GROSS PROFIT (LOSS)	(296)	784
OPERATING EXPENSES:
Research and development	3,642	8,744
Selling and marketing	3,178	6,613
General and administrative	6,387	9,125
Restructuring and impairment	982
Total operating expenses	14,189	24,482
LOSS FROM OPERATIONS	(14,485)	(23,698)
FINANCIAL EXPENSES, net:
Interest expenses	1,036	1,409
Other financial expenses (income)	60	(24)
Total financial expenses	1,096	1,385
LOSS BEFORE TAX EXPENSES	(15,581)	(25,083)
TAX EXPENSES	4	12
NET LOSS	$ (15,585)	$ (25,095)
NET LOSS PER SHARE - basic and diluted (in dollars per share)	$ (2.23)	$ (7.09)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic and diluted (in shares)	6,976,378	3,539,364

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Ordinary Shares [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at beginning at Dec. 31, 2013		$ 90,956	$ (82,316)	$ 8,640
Balance at beginning (in shares) at Dec. 31, 2013	3,398,297
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss			(25,095)	(25,095)
Issuance of shares and warrants		9,645		9,645
Issuance of shares and warrants (in shares)	725,927
Employee and non-employee share-based compensation expenses		4,138		4,138
Vesting of restricted stock (in shares)	17,196
Taxes withheld in respect of share issuance		(115)		(115)
Taxes withheld in respect of share issuance (in shares)	(4,568)
Balance at ending at Dec. 31, 2014		104,624	(107,411)	(2,787)
Balance at ending (in shares) at Dec. 31, 2014	4,136,852
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss			(15,585)	(15,585)
Issuance of shares and warrants	$ 1	12,431		12,432
Issuance of shares and warrants (in shares)	3,436,968
Employee and non-employee share-based compensation expenses		3,107		3,107
Vesting of restricted stock (in shares)	141,834
Taxes withheld in respect of share issuance		(113)		(113)
Taxes withheld in respect of share issuance (in shares)	(39,580)
Balance at ending at Dec. 31, 2015	$ 1	$ 120,049	$ (122,996)	$ (2,946)
Balance at ending (in shares) at Dec. 31, 2015	7,676,074

CONSOLIDATED STATEMENTS OF CHA6

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 1,315	$ 881

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$ (15,585)	$ (25,095)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		241	263
Impairment of royalties buyout	[1]	576
Loss from sale of property, plant and equipment		14
Change in liability for employees rights upon retirement		19	77
Financial expenses		249	350
Share-based compensation expenses		3,107	4,138
Loss (gains) on amounts funded in respect of employee rights upon retirement, net		3	(18)
Changes in operating asset and liability items:
Decrease in prepaid expenses		141	39
Decrease in trade receivables		230	1,220
Decrease in other receivables		217	28
Decrease (increase) in inventory		1,171	(331)
Decrease in trade payables		(397)	(659)
Increase (decrease) in other payable and advanced payment from customers		(1,582)	626
Net cash used in operating activities		(11,596)	(19,362)
CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease in restricted cash			93
Purchase of property, plant and equipment		(16)	(133)
Amounts funded in respect of employee rights upon retirement, net		(7)	(46)
Net cash used in investing activities		(23)	(86)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of shares and warrants		12,432	9,535
Repayment of long-term loan		(3,702)	(1,148)
Taxes withheld in respect of share issuance		(113)	(115)
Net cash provided by financing activities		8,617	8,272
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		(41)	(59)
DECREASE IN CASH AND CASH EQUIVALENTS		(3,043)	(11,235)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR		6,300	17,535
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR		3,257	6,300
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Income taxes		13	14
Interest paid		$ 863	1,082
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES:
Anti-dilution rights			$ 110
[1]	During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents.

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS a. General InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex coronary and vascular disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. In October 2014, the Company launched a limited market release of its carotid embolic prevention system (CGuard™ EPS), which combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. In January 2015, the Company received CE mark approval for the rapid exchange delivery system and launched CGuard in countries in Europe. The Company’s coronary products combining MicroNet and a bare-metal stent (MGuard Prime™ EPS) are marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Company markets its products through distributors in international markets, mainly in Europe and Latin America. b. Liquidity The Company has an accumulated deficit as of December 31, 2015, as well as net losses and negative operating cash flows in recent years. The Company expects to continue incurring losses and negative cash flows from operations until its products (primarily CGuard™) reach commercial profitability. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company does not have sufficient resources to fund operations beyond May 2016. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans include the continued commercialization of the Company’s products and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations. c. Reverse stock split On October 1, 2015, the Company effectuated a one-for-ten reverse stock split of its common stock. All related share and per share data have been retroactively applied to the financial statements and their related notes for all periods presented. See Note 10a.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations, royalty buyout and legal contingencies. b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates. c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation. d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents. e. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable are derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is f. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or market value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventories and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value. g. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements. h. Impairment in value of long-lived assets The Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized and the assets would be written down to their estimated fair values, based on expected future discounted cash flows. i. Revenue recognition Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer, collection is reasonably assured and product returns can be reliably estimated. The Company recognizes revenue net of value added tax (VAT). j. Research and development costs Research and development costs are charged to the statement of operations as incurred. k. Share-based compensation Employee option awards are classified as equity awards and accounted for using the grant-date fair value method. The fair value of share-based awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions. The Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach. In addition, certain share-based awards of the Company are performance based and dependent upon achieving certain goals. With respect to these awards, the Company estimates the expected pre-vesting award probability that the performance conditions will be achieved. The Company only recognizes expense for those shares that are expected to vest. l. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses -net”. m. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments. n. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $0.2 million and $0.8 million for the years ended December 31, 2015 and 2014, respectively. o. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. The calculation of diluted net loss per share excludes potential share issuances of common stock upon the exercise of share options and warrants, as the effect is anti-dilutive. For the years ended December 31, 2015 and 2014, all shares of common stock underlying outstanding options, warrants and restricted stock have been excluded from the calculation of the diluted loss per share since their effect was anti-dilutive. The total number of shares of common stock related to outstanding options and warrants and restricted stock excluded from the calculations of diluted loss per share were 5,004,836 and 1,352,326 for the years ended December 31, 2015 and 2014, respectively. p. Segment reporting The Company has one operating and reportable segment. q. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. r. Allocation of issuance proceeds When debt or equity is issued with other components that are subsequently measured at fair value, the proceeds are allocated first to such components (such as warrant liabilities and embedded derivatives in the debt that require bifurcation at their fair values) then the residual amount of the proceeds to the debt or equity. When the other components are classified in equity, the proceeds are allocated based on relative fair values. See Note 7. s. Recently issued accounting pronouncements 1. In April, 2015, the Financial Accounting Standards Board (“FASB”) issued guidance related to the presentation of Debt Issuance Costs. The new guidance requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The new guidance does not affect the recognition and measurement of debt issuance costs. The new guidance is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted for financial statements that have not been previously issued. The new guidance will be applied on a retrospective basis. 2. In May 2014, the Financial Accounting Standards Board (the “FASB”) issued ASC 606, Revenue from contracts with customers. The objective of the new revenue standard is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. The revenue standard contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services, based on a five step model that includes the identification of the contract with the customer and the performance obligations in the contract, determination of the transaction price, allocation of the transaction price to the performance obligations in the contract and recognizing revenue when (or as) the entity satisfies a performance obligation. The revenue standard is effective for annual periods beginning on or after December 15, 2016. The Company is currently evaluating the impact, if any, the adoption of this guidance will have on its consolidated financial statements. On July 9, 2015, the FASB approved a one-year deferral of the effective date of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, such that it is effective beginning on or after December 15, 2017 for public entities. Reporting entities may choose to adopt the standard as of the original effective date. 3. On July 22, 2015, the FASB issued Accounting Standards Update 2015-11, Simplifying the Measurement of Inventory, which requires that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) and the retail inventory method (RIM) are not impacted by the new guidance. The new guidance will be effective for public business entities in fiscal years beginning after December 15, 2016, including interim periods within those years. Prospective application is required. Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact of the standard on its consolidated financial statements.

RESTRUCTURING AND IMPAIRMENT

RESTRUCTURING AND IMPAIRMENT	12 Months Ended
	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND IMPAIRMENT	NOTE 3 - RESTRUCTURING AND IMPAIRMENT December 31, 2015 ($ in thousands) Employee termination costs (1) 305 Lease settlement (2) 101 Total restructuring $ 406 Impairment of royalties buyout (3) 576 Total restructuring and impairment $ 982 During the first quarter of 2015, the board of directors approved to curtail developing and promoting our bare metal stent platform and implementing another cost reduction/focused spending plan. The plan has four components: (i) reducing headcount; (ii) limiting the focus of clinical and development expenses to only carotid and neurovascular products; (iii) limiting sales and marketing expenses primarily to those related to the CGuard EPS stent launch; and (iv) reducing all other expenses (including conferences, travel, promotional expenses, executive cash salaries, director cash fees, rent, etc.). 1. During the year ended December 31, 2015, the company incurred $305,000 of costs associated with reducing the Company’s headcount. 2. On November 5, 2015, the Company entered into a second amendment (the “Second Lease Amendment”) to the lease agreement for its facilities in the U.S. Pursuant to the Second Lease Amendment and effective January 1, 2016, the Company agreed to reduce its leased space and surrender the released premises. The Company also agreed to pay transaction costs and settlement amount of $101,000. 3. During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents. The Company values Level 3 Royalties buyout using an internally developed valuation model, whose inputs include future MGuard Prime EPS sales and the derived royalties payments.

FAIR VALUE MEASURMENT

FAIR VALUE MEASURMENT	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASURMENT	NOTE 4 - FAIR VALUE MEASURMENT Items Measured at Fair Value on a Recurring Basis The following tables summarize the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs: Anti-Dilution Rights ($ in thousands) Balance as of January 1, 2014 $ 156 Total losses (gains) (realized and unrealized) - included in earnings - Financial expenses (income), net (46 ) Settlement by issuance shares (110 ) Balance as of December 31, 2014 $ - The Company valued Level 3 Anti- Dilution Rights using an internally developed valuation model, whose inputs include potential equity transactions (such as fund raising and share based awards), probability of completing successful fund raising during the relevant period and stock prices. The carrying amounts of financial instruments included in working capital approximate their fair value either because these amounts are presented at fair value or due to the relatively short-term maturities of such instruments. The fair value of the Loan (as defined in Note 7) approximated its carrying amount since it bears interest at rates that approximate current market rates.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 5 - PROPERTY, PLANT AND EQUIPMENT a. Composition of assets, grouped by major classifications, is as follows: December 31, 2015 2014 ($ in thousands) Cost: Computer equipment $ 221 $ 242 Office furniture and equipment 104 110 Machinery and equipment 961 951 Leasehold improvements 143 194 1,429 1,497 Less - accumulated depreciation and amortization (957 ) (875 ) Net carrying amount $ 472 $ 622 b. Depreciation and amortization expenses totaled approximately $152,000 and $163,000 for the years ended December 31, 2015 and 2014, respectively.

LIABILITY FOR EMPLOYEES RIGHT U

LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT	NOTE 6 - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to section 14 of the Israeli Severance Compensation Act, 1963, some of the Company’s employees are entitled to have monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 relieve the Company from any future severance payments to these employees. The severance pay liability of the Company for the rest of its Israeli employees, which reflects the undiscounted amount of the liability, is based upon the number of years of service and the latest monthly salary. The severance pay liability is partly covered by insurance policies and by regular deposits with recognized severance payment funds. The Company may only withdraw funds previously deposited for savings in connection with the payment of severance. The severance pay expenses were approximately $211,000 and $233,000 for the years ended December 31, 2015 and 2014, respectively. Defined contribution plan expenses were approximately $213,000 and $285,000 for the years ended December 31, 2015 and 2014, respectively. The Company expects contribution plan expenses in 2016 to be approximately $165,000.

LOAN

LOAN	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
LOAN	NOTE 7 – loan I. 2013 Security and Loan Agreement a. Loan and Security Agreement On October 23, 2013, the Company and InspireMD Ltd. entered into a Loan and Security Agreement (the “Loan and Security Agreement”), pursuant to which a lender made a term loan to the Company and InspireMD Ltd. in the aggregate amount of $10 million (the “Loan”). The annual interest rate on the Loan is prime plus 4%, but shall not be reduced below 10.5%. Payments under the Loan and Security Agreement are for the interest portion only for 9 months, followed by 30 monthly payments of principal and interest through the scheduled maturity date on February 1, 2017. The Company is permitted to prepay all or a portion of the Loan. However, any prepayments of the Loan will be subject to a penalty of (i) 2%, if the prepayment occurs within 12 months of the Loan being requested by the Company and InspireMD Ltd. (the “Advance Date”), (ii) 1%, if the prepayment occurs between 12 and 24 months after the Advance Date, and (iii) 0.5%, if the prepayment occurs more than 24 months after the Advance Date. The Company and InspireMD Ltd. will also pay the lender an aggregate end of term charge (the “End of Term Charge”) of $500,000 when the Loan is paid in full or matures. In addition, upon the occurrence of a change in control, the Company shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and all unpaid lender’s fees and expenses accrued to the date of the repayment (including the End of Term Charge) together with the penalties stated above. b. Security Documents On October 23, 2013, InspireMD Ltd. issued the lender a Fixed Charge Debenture and a Floating Charge Debenture (collectively, the “Israeli Security Agreements”) in order to create a security interest in all the assets and property of InspireMD Ltd., securing the Company’s and InspireMD Ltd.’s obligations under the Loan and Security Agreement. In addition, on October 23, 2013 and November 8, 2013, the Company entered into Deposit Account Control Agreements with the lender and two banking institutions in the US (the “Deposit Account Control Agreements”) in order to perfect the lender’s security interest in the Company’s bank account. Pursuant to the Loan and Security Agreement, the Israeli Security Agreements and the Deposit Account Control Agreement, the Company’s obligations to the lender are secured by a first priority perfected security interest in all of the assets and properties of the Company and InspireMD Ltd., other than the intellectual property of the Company and InspireMD Ltd. The Company is required under the Loan and Security Agreement to maintain at all times in the bank accounts under the Deposit Account Control Agreements, cash and cash equivalents which may include cash collected from Accounts Receivable by Inspire M.D Ltd. and InspireM.D GmbH within the previous 7 days, and cash transferred to Inspire M.D Ltd. for the settlement of Permitted Indebtedness within the following 7 days, in each unrestricted and unencumbered, in an aggregate amount of at least the lesser of (a) an amount equal to one hundred percent of the then outstanding principal amount of the Term Loan Advance and (b) an amount equal to seventy-five percent of the aggregate amount of all of Borrower’s worldwide cash and cash equivalents. As of December 31, 2015, the future principal payments obligation for the Loan were as follows: ($ in thousands) Year Ended December 31: 2016 4,234 2017 776 $ 5,010

RELATED PARTIES TRANSACTIONS

RELATED PARTIES TRANSACTIONS	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTIES TRANSACTIONS	NOTE 8 - RELATED PARTIES TRANSACTIONS a. CEO On January 26, 2015, the Company granted the CEO stock options to purchase 30,777 shares of the Company's common stock with an exercise price of $7.2 per share. The fair value of the options using the Black-Scholes option-pricing model, was approximately $131,000. On January 26, 2015 the Company granted the CEO 20,509 shares of restricted common stock which are subject to forfeiture until vested and which vest in three equal annual installments; On January 5, 2015, the CEO's employment agreement was amended such that, in lieu of 50% of the CEO's base cash salary, he would be paid an equivalent amount of shares of restricted common stock. On January 26, 2015, the Company issued 31,250 shares of restricted stock subject to a one year service condition, with a fair value of $225,000. On June 29, 2015, the Company amended the employment agreement with the Company’s CEO in order to, among other things, (i) modify the term of employment to end on June 30, 2016 unless earlier terminated by either party; and (ii) provide that, until the Company raises an aggregate of $5 million from investors, the CEO will receive (A) with respect to his employment in 2015, the 31,250 shares of restricted common stock of the Company, issued on January 26, 2015, as described above, will be subsequently adjusted based upon the volume-weighted average price of the Company’s common stock during the calendar year ended December 31, 2015 (or during the period from January 2, 2015 through his termination date if his employment is terminated upon his death or disability, by the CEO for good reason, or by the Company without cause prior to December 31, 2015) to represent the equivalent of 50% of the CEO’s base salary in 2015, and (B) with respect to his employment in 2016, 50% of his base salary from January 1, 2016 through June 30, 2016 to be paid in shares of restricted common stock of the Company valued at the fair market value of the Company’s common stock as of the market close on January 2, 2016. The amendment also amends those certain provisions in the Employment Agreement related to payments on termination of employment. On December 31, 2015, 63,825 shares of restricted stock were issued to the CEO, based on the adjusting formula stipulated in the amended agreement, as described above. See note 13b with respect to the fourth amendment to the CEO's employment agreement, entered into subsequent to December 31, 2015. The share based compensation arrangement with the Company's CEO was initially classified as an equity award, and was reclassified to a liability award on June 29, 2015 following the second amendment to the CEO's employment agreement, given the adjusting formula described above. On this date, the amount accumulated in additional paid in capital was reclassified as a liability, which was subsequently remeasured at fair value up to the date of its settlement. On December 31, 2015, the fair value of the liability just prior to such date, in the amount of $84,000, was carried to additional paid in capital. The Company recognized a total compensation expense of $84,000 in connection with the CEO's non-cash portion of his annual 2015 salary. During the year ended December 31, 2014, the Company granted the CEO stock options to purchase 39,968 shares of the Company's common stock with an exercise price of $29.70-$31.00 per share, and 18,273 shares of restricted stock, which vests in three equal annual installments. The fair value of the above options and restricted shares, using the Black-Scholes option-pricing model, was approximately $736,000 and $554,000, respectively. The CEO has an option to deliver a number of shares with an aggregate fair market value that equals or exceeds (to avoid the issuance of fractional shares) the required tax withholding payment resulted from the vesting of the restricted stock or from the exercise of the options. As of December 31, 2015 and 2014, 32,811 and 4,569 shares were withheld by the Company to satisfy tax withholding obligations. The payment, amounting to $81,000 and $115,000, was deducted from equity. On or before December 31 of each calendar year, the CEO will be eligible to receive an additional grant of equity awards equal, in the aggregate, to up to 0.5% of the Company’s actual outstanding shares of common stock on the date of grant, provided that the actual amount of the grant will be based on his achievement of certain performance objectives as established by the board, in its reasonable discretion, for each such calendar year. In connection with the equity compensation related to 2013 achievements, on January 29, 2014 the CEO was granted stock options to purchase 8,633 shares of the Company's common stock and 8,633 restricted shares, (included in total options and restricted shares granted to the CEO during 2014). In connection with the equity compensation related to 2014 achievements, on January 26, 2015 the CEO was granted stock options to purchase 5,300 shares of the Company's common stock and 5,300 restricted shares. On January 28, 2015, the Company’s board of directors approved an annual bonus for 2014 to the CEO in the amount of $69,105. In July 2015, the Company’s board of directors approved an annual bonus for 2015 to the CEO in the amount of $45,833. b. During the years ended December 31, 2015 and 2014, the Company granted stock options to directors to purchase a total of 138,541 and 33,500 shares of the Company’s common stock, respectively. The options have exercise prices of $1.7 - $7.8 and $31, per share, respectively, which were the fair market value of the Company’s common stock on the date of each respective grant. The options granted in 2014 are subject to a three-year vesting period with one-third of such awards vesting each year. Of the 138,541 options granted in 2015, 107,744 options were in lieu of cash compensation that was owed to them for their services as directors for the third and fourth quarters of 2014 and the first through third quarter of 2015 and are fully vested as of their grant date and the remaining options are subject to a three-year vesting period, with one-third of such awards vesting each year. The fair value of the above options, using the Black-Scholes option-pricing model, was approximately $338,000 and $636,000, respectively. c Balances with related parties: December 31, 2015 2014 ($ in thousands) Current liabilities: Other accounts payable $ 132 $ 241 d Transactions with related parties: Year ended December 31, 2015 2014 ($ in thousands) Total expenses $ 1,892 $ 3,269

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENT AND CONTINGENT LIABILITIES	NOTE 9 - COMMITMENTS AND CONTINGENT LIABILITIES a. Lease commitments: 1) On December 13, 2011, the Company entered into a lease agreement for a facility in Israel, which expired in December 2014. The Company had the option, under the agreement, to extend the agreement for two additional two year periods, for a total of four years. The Company extended the agreement for two additional years. In December 2013, the Company entered into a lease agreement for its facilities in the U.S which expires in February 2018. The Company has the right to terminate the lease agreement effective Febuary 1, 2017 upon 9 months prior written notice, as stipulated in the agreement. In August 2014, the Company entered into an amendment (the “First Lease Amendment”) to the lease agreement for its facilities in the U.S. Pursuant to the First Lease Amendment, amongst other things, the Company agreed to lease additional space and extend the expiration of the agreement to February 2019. On November 5, 2015, the Company entered into a second amendment (the “Second Lease Amendment”) to the lease agreement for its facilities in the U.S. See Note 3. On September 1, 2015 the Company signed a sublease agreement for part of its U.S. facilities. The agreement will terminate on August 31, 2017. Rent expense included in the consolidated statements of operations totaled approximately $383,000 and $388,000 for the years ended December 31, 2015 and 2014, respectively. The rent expense for the year ended December 31, 2015 excludes $101,000, which is recorded under “Restructuring and impairment” in the consolidated statements of operations. See Note 3. As of December 31, 2015, the aggregate future minimum lease obligations for office rent under non-cancelable operating lease agreements were as follows: ($ in thousands) Year Ended December 31: 2016 $ 320 2017 5 $ 325 2) The Company leases its motor vehicles under operating lease agreements. As of December 31, 2015, the aggregate non-cancelable future minimum lease obligations for motor vehicles were approximately $6,000. b. License Agreement: On August 22, 2013, the Company, InspireMD Ltd. and a licensor entered into an amendment to the License Agreement, pursuant to which the Company and the Licensor agreed to amend the royalty fee from 2.9% of all net sales during the term of the agreement to (i) 2% of the first $10.56 million of net sales from July 1, 2013 through June 30, 2015, provided that the Company makes an advance royalty payment of $192,000 on the date of the amendment, (ii) 2.5% of net sales in excess of $10.56 million from July 1, 2013 through June 30, 2015, payable within 45 days of June 30, 2015, and (iii) 2.9% of all net sales beginning on July 1, 2015. The above referenced advance royalty payment has been included in long term prepaid expenses. During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents. The expense is recorded under “Restructuring and impairment” in the consolidated statements of operations. Royalties expenses for the years ended December 31, 2015 and 2014 amounted to approximately $149,000 and $148,000, respectively. c. Liens and pledges 1) The Company’s obligations under the Loan and Security Agreement were secured by the Israeli Security Agreements and the Deposit Account Control Agreements on all of the assets and properties of the Company and InspireMD Ltd., other than the intellectual property of the Company and InspireMD Ltd. See Note 7. d. Litigation: In July 2012, a purported assignee of options in InspireMD Ltd. submitted a statement of claim against the Company, InspireMD Ltd., and the Company’s former CEO and President for a declaratory and enforcement order that it is entitled to options to purchase 8,364 shares of the Company’s common stock at an exercise price of $7.60 per share. In December 2014 the court accepted a motion to dismiss the former CEO and president from the lawsuit. On May 27, 2015 the Company and the assignee of options accepted a settlement agreement pursuant to which the claim was removed and the plaintiff waived his entire claim against the Company, in consideration of the Company's consent to allow him to exercise 5,855 options of the Company's shares of common stock. In December 2012, a former service provider of InspireMD GmbH filed a claim with the Labor Court in Buenos Aires, Argentina in the amount of $193,378 plus interest (6% in dollars or 18.5% in pesos), social benefits, legal expenses and fees (25% of the award) against InspireMD Ltd. and InspireMD GmbH. The Company's management, after considering the views of its legal counsel as well as other factors, recorded a provision of $250,000 in the financial statements for the quarter ended December 31, 2012. In March 2015, the interest rate made by the Court of Appeal in Argentina was increased retroactively, which resulted in the provision increasing to $340,000. The related expense for the increase of $90,000 was recorded to “General and administrative” within the Consolidated Statements of Operations. The Company settled with the plaintiff in the amount of $80,000 plus $20,000 for legal fees, which was approved by the Labor Court and paid by the Company in March 2016 resulting in the provision decreasing to $100,000. The related decrease in provision amounting to $240,000 was recorded to “General and administrative” within the Consolidated Statements of Operations. The Company received written communication from a distributor to provide unspecified compensation for pre-paid goods subject to the voluntary field action. After considering the views of its legal counsel as well as other factors, the Company’s management believes that a loss from any related future proceedings would range from a minimal amount up to 1,075,000 Euros and is reasonably possible. In November 2015, the Company received written communication from a service provider to remit payment amounting to $1,965,000. Given the preliminary stage, the Company’s management and legal counsel cannot estimate the outcome of any legal proceedings or settlements, however believes that neither a court loss nor settlement are probable.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
EQUITY	NOTE 10 – EQUITY a. Share capital On September 9, 2015, the stockholders approved the authorization of the board of directors, in its discretion, to amend the Amended and Restated Certificate of Incorporation of the Company to effect a reverse stock split of the Company’s common stock at a ratio of one-for-ten and to reduce the number of authorized shares of the Company’s common stock from 125 million shares to 50 million shares. The Company’s common stock is listed on the NYSE MKT. On September 30, 2015, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a one-for-ten reverse stock split of its common stock, par value $0.0001 per share (the “Reverse Stock Split”), effective as of October 1, 2015, which decreased the number of issued and outstanding shares of common stock and restricted shares of common stock from 78 million shares to 7.8 million shares. The Company’s authorized common stock was decreased from 125 million shares to 50 million shares. Accordingly, as of December 31, 2015, the Company has authorized 55,000,000 shares of capital stock, par value $0.0001 per share, of which 50,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock. All related share and per share data have been retroactively applied to the financial statements and their related notes for all periods presented. Pursuant to the terms of 2011 SPA that provided these investors with certain anti-dilution protections until March 31, 2014. The Company issued the purchasers or their assigns an aggregate of 84,289 shares of common stock through 2014. The related expense has been recorded to “Financial expenses (income), net” within the consolidated statements of operations in the relevant periods. On August 15, 2014, the Company sold 94,800 shares of its common stock pursuant to its at-the-market (ATM) issuance sales agreement with MLV & Co. LLC. These sales resulted in net proceeds to the Company of approximately $2.2 million. On November 7, 2014, the Company sold 626,189 shares of its common stock and warrants to purchase 313,100 shares of common stock in a registered direct offering (the “2014 Offering”). The common stock was sold at a negotiated purchase price of $13 per share, and each purchaser received a warrant to purchase 0.5 of a share of common stock for each share of common stock that it purchased in the offering. The warrants, which are classified in equity, are non-exercisable for six months and have a term of exercise of 42 months from the date of issuance and an exercise price of $17.5. This offering resulted in net proceeds to the Company of approximately $7.4 million after deducting placement agent fees and other estimated offering expenses. On March 9, 2015, the Company sold 3,436,968 shares of its common stock and warrants to purchase 3,436,968 shares of common stock in a registered direct offering. Each purchaser received a warrant to purchase one share of common stock for each share of common stock that it purchased in the offering. The warrants, which are classified as equity, are exercisable immediately and have a term of exercise of 5 years from the date of issuance and an exercise price of $5.50. This offering resulted in net proceeds to the Company of approximately $12.4 million after deducting placement agent fees and other offering expenses. b. Share-Based Compensation 1. On March 28, 2011, the board of directors and stockholders of the Company adopted and approved the InspireMD, Inc. 2011 UMBRELLA Option Plan (the “Umbrella Plan”) which expires on March 27, 2021. Under the Umbrella Plan, as subsequently amended, the Company reserved 500,000 shares of common stock as awards to employees, consultants, and service providers. As of December 31, 2015, the Company had reserved 18,603 shares of common stock for issuance under the plans as described above. On December 16, 2013, the board of directors and stockholders of the Company adopted and approved the InspireMD, Inc. 2013 Long-Term Incentive Plan (the “2013 Plan”). Under the 2013 Plan, the Company reserved 500,000 shares of common stock for awards to employees, officers, directors, consultants, and service providers. On September 9, 2015, the stockholders approved an amendment to the 2013 Plan to increase the number of shares of common stock available for issuance pursuant to awards under the Plan by 470,000 shares of common stock, to a total of 970,000 shares of common stock (the "Plan Amendment"). As of December 31, 2015, the Company had reserved 439,930 shares of common stock for issuance under the plans as described above. The 2013 Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights, and other awards, which may be granted singly, in combination, or in tandem. The 2013 Plan is administered by the Company’s compensation committee. U.S. federal income tax consequences relating to the transactions described under the Umbrella Plan are set forth in Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and treasury regulations in 2004 to regulate all types of deferred compensation. Pursuant to the current Section 102 of the Israeli Tax Ordinance, which came into effect on January 1, 2003, options may be granted through a trustee (i.e., Approved 102 Options) or not through a trustee (i.e., Unapproved 102 Options). 2. During the years ended December 31, 2015 and 2014, the Company granted stock options to the CEO, employees and directors to purchase a total of 214,499 and 184,652 shares of the Company’s common stock, respectively. The options have exercise prices ranging from $1.70-$8.30 and $11.40-$32.30 per share, respectively, which were the fair market value of the Company’s common stock on the date of each respective grant. The fair value of these options, using the Black-Scholes option-pricing model, was approximately $660,000 and $3,279,000, respectively. Of the 214,499 stock options granted in 2015, 107,744 options are fully vested as of their grant date and the remaining options are subject to a three-year vesting period with one-third of such awards vesting each year. The options granted in 2014 are subject to a three-year vesting period with one-third of such awards vesting each year See also Note 8a for stock options grants to the CEO and directors. Out of the 184,652 stock options granted during the year ended December 31, 2014, 45,001 stock options were granted to the COO of the Company, who also serves as one of the Company's directors. 3. During the year ended December 31, 2015 and 2014, the Company granted to the CEO, employees and directors 196,178 and 65,076 restricted shares of the Company’s common stock, respectively. The fair value of these restricted shares was approximately $1,157,000 and $1,916,000. Of the 196,178 restricted shares granted during the year ended December 31, 2015, 43,300 restricted shares are subject to a one-year vesting period, 9,250 restricted shares are fully vested as of their grant date and are subject to a 6 month lock up period, 63,825 restricted shares are fully vested as of their grant date, 32,914 restricted shares are subject to a six-month vesting period and 46,889 restricted shares are subject to a three-year vesting period, with one-third of such awards vesting each year. The 65,076 restricted shares granted during the year ended December 31, 2014 are subject to a three-year vesting period with one-third of such awards vesting each year. Out of the 65,076 restricted shares mentioned above, 15,000 restricted shares were granted to the COO of the Company, who also serves as one of the Company's directors. 4. The following table summarizes information about warrants and share options to employees: Year ended December 31, 2015 2014 Number of warrants Weighted Number of warrants and Weighted Outstanding - beginning of period 537,018 $ 40.10 368,818 $ 45.50 Granted 214,499 $ 5.31 184,652 $ 29.10 Forfeited (37,830 ) $ 30.68 (16,452 ) $ 39.00 Outstanding -end of period 713,687 $ 30.10 537,018 $ 40.10 Exercisable at the end of the period 344,787 $ 46.37 229,201 $ 54.80 The following table summarizes information about warrants and share options to non-employees: Year ended December 31, 2015 2014 Number of warrants Weighted average exercise price Number of warrants and Weighted Outstanding - beginning of period 139,902 $ 44.80 154,315 $ 45.70 Forfeited (5,608 ) $ 30.67 (14,413 ) $ 54.40 Outstanding - end of period 134,294 $ 45.37 139,902 $ 44.80 Exercisable at the end of the period 133,888 $ 45.36 139,140 $ 44.70 5. The following table summarizes information about restricted shares to employees: Year ended December 31, 2015 2014 Number of restricted shares Number of restricted shares Outstanding - beginning of period 103,016 54,654 Granted 196,178 65,076 Forfeited (10,145 ) (718 ) Vested (141,834 ) (15,996 ) Outstanding - end of period 147,215 103,016 The following table provides additional information about all warrants and options outstanding and exercisable: Outstanding as of December 31, 2015 Exercise price Warrants and Weighted Warrants $0-$8.3 251,637 8.19 38,709 $19.7-$29.8 227,249 7.80 117,081 $30.5-$34 87,202 7.67 43,065 $40.5-$49.285 93,283 5.78 91,210 $60-$78 172,360 2.92 172,360 $80-$100 16,250 5.42 16,250 847,981 6.64 478,675 The weighted average of the remaining contractual life of total vested and exercisable warrants and options as of December 31, 2015 was 5.04 years. The aggregate intrinsic value of the total exercisable warrants and options as of December 31, 2015 was approximately $25,563. The weighted average fair value of warrants and options granted was approximately $3.11 and $17.80 for the years ended December 31, 2015 and 2014, respectively. The weighted average fair value of warrants and options granted was estimated using the Black-Scholes option-pricing model. 1. The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the years ended December 31, 2015 and 2014: Year ended December 31, 2015 2014 Expected life 5-6.5 years 5.5-6.5 years Risk-free interest rates 1.41%-1.71 % 1.64%-2.18 % Volatility 62.68%-71.12 % 62.89%-68 % Dividend yield 0 % 0 % The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration the option’s contractual life and the vesting periods (for non-employees, the expected term is equal to the option’s contractual life). The Company estimates its forfeiture rate based on its employment termination history, and will continue to evaluate the adequacy of the forfeiture rate based on analysis of employee turnover behavior and other factors (for non-employees the forfeiture rate is nil). The annual risk-free rates are based on the yield rates of zero coupon non-index linked U.S. Federal Reserve treasury bonds as both the exercise price and the share price are in dollar terms. The Company’s expected volatility is derived from a blended volatility, based on its historical data and that of a peer group of public companies. 2. As of December 31, 2015, the total unrecognized compensation cost on employee and non-employee stock options and restricted shares, related to unvested stock-based compensation, amounted to approximately $1.75 million. This cost is expected to be recognized over a weighted-average period of approximately 0.82 years. This expected cost does not include the impact of any future stock-based compensation awards. The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations: Year ended December 31, 2015 2014 ($ in thousands) Cost of revenues $ 8 $ 13 Research and development 716 534 Sales and marketing 179 446 General and administrative 2,145 3,145 Restructuring and impairment 59 $ 3,107 $ 4,138 c. At-the-Market Agreement On October 23, 2013, the Company entered into an at-the-market issuance sales agreement, or the Sales Agreement, with MLV & Co. LLC pursuant to which The Company may issue and sell shares of the Company common stock having an aggregate offering price of up to $40 million directly on the NYSE MKT or sales made to or through a market maker other than on an exchange. With the Company’s prior written consent, sales may also be made in negotiated transactions and/or any other method permitted by law. MLV & Co. LLC will receive a 3% commission from the gross proceeds of any sales. Subject to the terms and conditions of the Sales Agreement, MLV & Co. LLC will use its commercially reasonable efforts to sell the shares of the Company’s common stock from time to time, based upon the Company’s instructions (including any price, time or size limits or other parameters or conditions that the Company may impose). The Company is not obligated to make any sales of common stock under the Sales Agreement and no assurance can be given that the Company will sell any shares under the Sales Agreement, or, if the Company does, as to the price or amount of shares that the Company will sell, or the dates on which any such sales will take place. The Sales Agreement may be terminated by either party at any time upon 10 days’ notice to the other party, or by MLV & Co. LLC at any time in certain circumstances, including the occurrence of a material adverse effect to the Company. In addition, the Sales Agreement will automatically terminate upon the sale of all common stock subject to the Sales Agreement. During the year ended December 31, 2014, the Company sold 94,800 shares of its common stock pursuant to its at-the-market issuance sales agreement with MLV & Co. LLC. These sales resulted in net proceeds to the Company of approximately $2.2 million. Following the 2014 Offering, the Company is prohibited from entering into any variable rate transactions which may impair its ability to make sales under our at-the-market issuance sales agreement absent the consent of the investors in the 2015 Offering until March 9, 2017.

TAXES ON INCOME

TAXES ON INCOME	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
TAXES ON INCOME	NOTE 11 - TAXES ON INCOME a. Tax laws applicable to the Company and its subsidiaries Taxation in the United States InspireMD, Inc. is taxed under U.S. tax laws. Accordingly, the applicable corporate tax rate is 34%. Taxation in Israel InspireMD Ltd. is taxed under the Israeli Income Tax Ordinance as a corporate tax rate of 26.5%. Taxation in Germany InspireMD GmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825% and trade tax rate of 17.15%. Taxation in UK InspireMD UK is taxed according to the tax laws in the UK. Accordingly, the applicable tax rate is a corporate tax rate of 20%. b. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Law”): 1. InspireMD Ltd. has been granted a “Beneficiary Enterprises” status under the Investment Law including Amendment No. 60 thereof, which became effective in April 2005. The tax benefits derived from any such Beneficiary Enterprise relate only to taxable profits attributable to the specific program of investment to which the status was granted. The main benefit, to which InspireMD Ltd. is entitled, conditional upon the fulfilling of certain conditions stipulated by the above law, is a two-year exemption and five years of a reduced tax rate of 25% from tax on income derived from beneficiary activities in facilities in Israel. The two-year exemption starts only when the Company starts to pay taxes after using all carryforward tax losses. The tax benefit period is twelve years from the year of election, which means that after a year of election, the two-year exemption and five years of reduced tax rate can only be used within the next twelve years. The Company elected the year 2007, as a year of election and 2011 as an additional year of election. In the event of a distribution of tax-exempt income attributable to "Beneficiary Enterprises" as a cash dividend, the Company will be required to pay tax at a rate of 25% on the amount distributed. In addition, dividends originating from income attributable to the "Beneficiary Enterprises" will be subject to a 15% withholding tax. Should InspireMD Ltd. derive income from sources other than the “Beneficiary Enterprises” during the period of benefits, such income shall be taxable at the regular corporate tax rate. 2. Conditions for entitlement to the benefits The entitlement to the above benefits is conditional upon InspireMD Ltd. fulfilling the conditions stipulated by the law, regulations published thereunder and the instruments of approval for the specific investments in approved assets. In the event of failure to comply with these conditions, the benefits may be cancelled and InspireMD Ltd. may be required to refund the amount of the benefits, in whole or in part, with the addition of interest. The Company opted not to apply for Preferred Enterprise status. c. Carry forward tax losses As of December 31, 2015, InspireMD Ltd. had a net carry forward tax loss of approximately $52 million. Under Israeli tax laws, the carry forward tax losses can be utilized indefinitely. The Company had a net carry forward tax loss of approximately $29 million. Under U.S. tax laws, the Company’s tax losses can be utilized two years back and twenty years forward. As such the Company's carry forward tax losses will begin to expire on December 31, 2031. d. Loss before income taxes The components of loss before income taxes are as follows: Year ended December 31, 2015 2014 ($ in thousands) Profit (loss) before taxes on income: InspireMD, Inc. $ (6,131 ) $ (11,671 ) Subsidiaries (9,450 ) (13,412 ) $ (15,581 ) $ (25,083 ) Current taxes on income The following is a reconciliation of the theoretical tax expense, assuming all income was taxed at the regular tax rates applicable to the Company in the U.S. and the actual tax expense: Year ended December 31, 2015 2014 ($ in thousands) Loss before taxes on income, as reported in the statements of operations $ 15,581 $ 25,083 Theoretical tax benefit (5,297 ) (8,529 ) Decrease in tax benefit resulting from permanent differences 273 390 Increase (decrease) in taxes on income resulting from the computation of deferred taxes at a rate which is different from the theoretical rate, and other 716 2,038 Difference between income reported for tax purposes and income for financial reporting purposes — net 50 1,100 Decrease in theoretical tax benefit resulting from subsidiaries different tax rate (53 ) (73 ) Change in corporate tax rates - Change in valuation allowance 4,315 5,086 $ 4 $ 12 As of December 31, 2015 and 2014, the Company determined that it was more likely than not that the benefit of the operating losses would not be realized and consequently, management concluded that full valuation allowances should be established regarding the Company’s deferred tax assets. The changes in the valuation allowance for the year ended December 31, 2015 and 2014 were as follows: Year ended December 31, 2015 2014 ($ in thousands) Balance at the beginning of the year $ 24,655 $ 19,569 Changes during the year 4,451 5,086 Balance at the end of the year $ 29,106 $ 24,655 e. Accounting for Uncertain Tax position The Company has no uncertain tax positions as of December 31, 2015. All of the above amounts of unrecognized tax benefits would affect the effective tax rate if recognized. A summary of open tax years by major jurisdiction is presented below: Jurisdiction Years U.S. 2012-2015 Israel 2012-2015 Germany 2010-2015 United Kingdom 2014-2015 f. Deferred income tax: December 31, 2015 2014 ($ in thousands) Short-term: Allowance for doubtful accounts $ 74 $ 89 Provision for vacation and recreation pay 105 59 179 148 Long-term: R&D expenses 1,326 1,738 Share-based compensation 3,873 2,990 Carry forward tax losses 23,674 19,729 Accrued severance pay, net 54 50 28,927 24,507 Less-valuation allowance (29,106 ) (24,655 ) $ - $ -

SUPPLEMENTARY FINANCIAL STATEME

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	NOTE 12 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION Balance sheets: a. Accounts receivable: The changes in “Allowance for doubtful accounts” during the years ended December 31, 2015 and 2014 are as follows: Year ended December 31, 2015 2014 ($ in thousands) Balance at beginning of period $ 337 $ 405 Additions during the period 72 35 Deductions during the period (49 ) (57 ) Exchange rate differences (14 ) (46 ) Balance at end of period $ 346 $ 337 b. Inventories: December 31, 2015 2014 ($ in thousands) Finished goods $ 301 $ 1,273 Work in process 307 326 Raw materials and supplies 145 325 $ 753 $ 1,924 For the years ended December 31, 2015 and 2014, the Company recorded expenses for slow moving inventory in the amounts of $588,000 and $129,000, respectively. c. Voluntary Field Corrective Action On April 30, 2014, the Company initiated a voluntary field corrective action (“VFA”) of its MGuard Prime EPS to address the issue of stent retention following reports of MGuard Prime stent dislodgements. On June 18, 2014, the Company received approval from the European regulatory agency to resume the manufacturing of the MGuard Prime stent with a modified stent securement process. The Company also received approval to modify and re-deploy existing MGuard Prime stents that were sent to the Company by clinical and commercial sites worldwide. These products have been modified and shipped to direct hospital customers and the majority of its distributor partners, who have begun shipping modified product back into hospital accounts. The Company began shipping products to new customers in the Company’s direct markets in Western Europe in October 2014. The VFA had an adverse impact on both the commercial and clinical activities relating to the MGuard Prime EPS from the date of initiation through December 31, 2014. The expenses associated with the modifications that were performed as a result of the VFA are approximately $377,000. These expenses were recorded in “Cost of revenues” through the end of 2015. In addition, as a result of the VFA, the Company suspended enrollment in the MASTER II trial, which had been previously launched to support its investigational device exemption application for MGuard Prime EPS with the U.S. Food and Drug Administration (“FDA”), pending a review by the FDA of the manufacturing improvements to the MGuard Prime EPS. The FDA approved the re-commencement of the MASTER II trial in October 2014. Notwithstanding FDA approval to re-commence enrollment of the Master II trial, in light of current market conditions moving toward the use of drug-eluting stents (DES) over bare-metal stents, the Company elected not to resume enrollment in the MASTER II trial. As a result of this change, the MASTER II trial will no longer be an FDA registration trial. d. Accounts payable and accruals-other: December 31, 2015 2014 ($ in thousands) Employees and employee institutions $ 412 $ 1,022 Accrued vacation and recreation pay 377 410 Accrued clinical trials expenses 582 1,016 Provision for sales commissions 80 120 Accrued expenses 552 993 Taxes payable 3 15 $ 2,006 $ 3,576

ENTITY WIDE DISCLOSURES

ENTITY WIDE DISCLOSURES	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
ENTITY WIDE DISCLOSURES	NOTE 13 - ENTITY WIDE DISCLOSURES Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: Year ended December 31, 2015 2014 ($ in thousands) Germany $ 519 $ 286 Italy 415 96 Brazil 238 95 Belarus 226 285 Middle East 94 792 Other 818 1,264 $ 2,310 $ 2,818 By product: Year ended December 31, 2015 2014 ($ in thousands) MGuard* 1,607 2,797 CGuard 703 21 $ 2,310 $ 2,818 *Includes revenue from sales of both MGuard Prime and MGuard. By principal customers: Year ended December 31, 2015 2014 Customer A 11 % 7 % Customer B 10 % 10 % Customer C 21 % All tangible long lived assets are located in Israel.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 – SUBSEQUENT EVENTS On January 16, 2016, the Board of Directors appointed a new director as a Vice Chairman of the Board, effective as of January 22, 2016, with a term expiring at the Company’s 2017 annual meeting of stockholders. In connection with his appointment, the new director will be granted an option to purchase 780,000 shares of the Company’s common stock on April 30, 2016 at an exercise price equal to the closing fair market value of the Common Stock on the date of grant on April 30, 2016, subject to the terms and conditions of the 2013 Plan. Options to purchase 195,000 shares of Common Stock vest and become exercisable immediately upon the time of grant, and, until all 780,000 options shall have vested, options to purchase 195,000 shares of common stock will vest and become exercisable each time upon (i) the Company raising at least $15 million through an equity offering; (ii) the Company’s market cap becoming equal to or greater than $25 million; (iii) the Company receiving research coverage by three new analysts at a leading investment bank; or (iv) the tripling of the Company’s market cap from the date of appointment. Any of the foregoing conditions, if achieved following the director’s appointment but prior to April 30, 2016, will be deemed satisfied on the date of grant. However, in the event (i) of the director’s death or permanent disability, (ii) a change in control (as defined in the Plan) or (iii) if the director is asked to resign for any reason other than cause (as defined in the Company’s form of Nonqualified Stock Option Agreement under its Plan), the options shall vest immediately in full. The options have a term of 10 years from the date of grant and may be exercised for either cash or on a cashless basis. On January 21, 2016, the Company and the Company’s CEO, entered into a fourth amendment to the CEO’s Employment Agreement dated as of January 3, 2013, as first amended on April 24, 2013, and further amended on January 5, 2015, and on June 29, 2015, by and between the Company and the CEO, in order to, among other things, (i) modify the term of the CEO’s employment to end on the earlier of June 30, 2016 or the date upon which a new president and/or chief executive officer (or executive performing a similar role) commences employment with the Company (or, if such individual is promoted internally, the date such individual is promoted to the position of president and/or chief executive officer); and (ii) provide that, during the remaining term of his employment, the CEO will receive (A) 50% of his base salary in cash payments, for all days that the CEO works during the remaining term of his employment, at the monthly rate of $18,750, payable in accordance with the Company’s regular payroll practices, and (B) a lump-sum payment equivalent to 50% of the CEO’s base salary through June 30, 2016, at the monthly rate of $18,750, payable within 20 business days from the earlier of (x) the Company raising an aggregate of $5 million from investors, or (y) June 30, 2016. On January 26, 2016 the Company entered into an option cancellation and release agreement with certain directors, the CEO and CFO (“the Optionholders”), pursuant to which the parties agreed to cancel options to purchase an aggregate of 422,443 shares of common stock of the Company at exercise prices ranging from $7.20 to $100.00 previously granted to each of the Optionholders. On March 21, 2016, the Company sold 1,900,000 shares of its common stock and warrants to purchase 950,000 shares of common stock in an underwritten public offering. The common stock was sold at a price of $0.59 per share and each purchaser received a warrant to purchase one half of one share of common stock for each share of common stock that it purchased in the offering. The warrants are exercisable immediately and have a term of exercise of 5 years from the date of issuance and an exercise price of $0.59. This offering resulted in gross proceeds to the Company of approximately $1.1 million. On March 21, 2016, the Company sold 1,033,051 shares of its common stock and warrants to purchase 516,526 shares of common stock in an underwritten private offering. The common stock was sold at a price of $0.59 per share and each purchaser received a warrant to purchase one half of one share of common stock for each share of common stock that it purchased in the offering. The warrants are exercisable immediately and have a term of exercise of 5 years from the date of issuance and an exercise price of $0.59. This offering resulted in gross proceeds to the Company of approximately $0.6 million. These sales of securities on March 21, 2016 resulted in aggregate net proceeds to the Company of approximately $1.4 million after deducting underwriting discount, placement agent fees and other offering expenses.

SIGNIFICANT ACCOUNTING POLICI22

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of estimates	a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations, royalty buyout and legal contingencies.
Functional currency	b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates.
Principles of consolidation	c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.
Cash and cash equivalents	d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents.
Concentration of credit risk and allowance for doubtful accounts	e. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable are derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is
Inventory	f. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or market value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventories and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value.
Property, plant and equipment	g. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of thea improvements.
Impairment in value of long-lived assets	h. Impairment in value of long-lived assets The Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized and the assets would be written down to their estimated fair values, based on expected future discounted cash flows.
Revenue recognition	i. Revenue recognition Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer, collection is reasonably assured and product returns can be reliably estimated. The Company recognizes revenue net of value added tax (VAT).
Research and development costs	j. Research and development costs Research and development costs are charged to the statement of operations as incurred.
Share-based compensation	k. Share-based compensation Employee option awards are classified as equity awards and accounted for using the grant-date fair value method. The fair value of share-based awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions. The Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach. In addition, certain share-based awards of the Company are performance based and dependent upon achieving certain goals. With respect to these awards, the Company estimates the expected pre-vesting award probability that the performance conditions will be achieved. The Company only recognizes expense for those shares that are expected to vest.
Uncertain tax positions	l. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses -net”.
Deferred income taxes	m. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments.
Advertising	n. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $0.2 million and $0.8 million for the years ended December 31, 2015 and 2014, respectively.
Net loss per share	o. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. The calculation of diluted net loss per share excludes potential share issuances of common stock upon the exercise of share options and warrants, as the effect is anti-dilutive. For the years ended December 31, 2015 and 2014, all shares of common stock underlying outstanding options, warrants and restricted stock have been excluded from the calculation of the diluted loss per share since their effect was anti-dilutive. The total number of shares of common stock related to outstanding options and warrants and restricted stock excluded from the calculations of diluted loss per share were 5,004,836 and 1,352,326 for the years ended December 31, 2015 and 2014, respectively.
Segment reporting	p. Segment reporting The Company has one operating and reportable segment.
Fair value measurement:	q. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
Allocation of issuance proceeds	r. Allocation of issuance proceeds When debt or equity is issued with other components that are subsequently measured at fair value, the proceeds are allocated first to such components (such as warrant liabilities and embedded derivatives in the debt that require bifurcation at their fair values) then the residual amount of the proceeds to the debt or equity. When the other components are classified in equity, the proceeds are allocated based on relative fair values. See Note 7.
Recently issued accounting pronouncements	s. Recently issued accounting pronouncements 1. In April, 2015, the Financial Accounting Standards Board (“FASB”) issued guidance related to the presentation of Debt Issuance Costs. The new guidance requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The new guidance does not affect the recognition and measurement of debt issuance costs. The new guidance is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted for financial statements that have not been previously issued. The new guidance will be applied on a retrospective basis. 2. In May 2014, the Financial Accounting Standards Board (the “FASB”) issued ASC 606, Revenue from contracts with customers. The objective of the new revenue standard is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. The revenue standard contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services, based on a five step model that includes the identification of the contract with the customer and the performance obligations in the contract, determination of the transaction price, allocation of the transaction price to the performance obligations in the contract and recognizing revenue when (or as) the entity satisfies a performance obligation. The revenue standard is effective for annual periods beginning on or after December 15, 2016. The Company is currently evaluating the impact, if any, the adoption of this guidance will have on its consolidated financial statements. On July 9, 2015, the FASB approved a one-year deferral of the effective date of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, such that it is effective beginning on or after December 15, 2017 for public entities. Reporting entities may choose to adopt the standard as of the original effective date. 3. On July 22, 2015, the FASB issued Accounting Standards Update 2015-11, Simplifying the Measurement of Inventory, which requires that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) and the retail inventory method (RIM) are not impacted by the new guidance. The new guidance will be effective for public business entities in fiscal years beginning after December 15, 2016, including interim periods within those years. Prospective application is required. Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact of the standard on its consolidated financial statements.

RESTRUCTURING AND IMPAIRMENT (T

RESTRUCTURING AND IMPAIRMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
Schedule of restructuring and impairment	December 31, 2015 ($ in thousands) Employee termination costs (1) 305 Lease settlement (2) 101 Total restructuring $ 406 Impairment of royalties buyout (3) 576 Total restructuring and impairment $ 982 During the first quarter of 2015, the board of directors approved to curtail developing and promoting our bare metal stent platform and implementing another cost reduction/focused spending plan. The plan has four components: (i) reducing headcount; (ii) limiting the focus of clinical and development expenses to only carotid and neurovascular products; (iii) limiting sales and marketing expenses primarily to those related to the CGuard EPS stent launch; and (iv) reducing all other expenses (including conferences, travel, promotional expenses, executive cash salaries, director cash fees, rent, etc.). 1. During the year ended December 31, 2015, the company incurred $305,000 of costs associated with reducing the Company’s headcount. 2. On November 5, 2015, the Company entered into a second amendment (the “Second Lease Amendment”) to the lease agreement for its facilities in the U.S. Pursuant to the Second Lease Amendment and effective January 1, 2016, the Company agreed to reduce its leased space and surrender the released premises. The Company also agreed to pay transaction costs and settlement amount of $101,000. 3. During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents.

FAIR VALUE MEASURMENT (Tables)

FAIR VALUE MEASURMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of fair value measurements are estimated utilizing Level 3	The following tables summarize the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs: Anti-Dilution Rights ($ in thousands) Balance as of January 1, 2014 $ 156 Total losses (gains) (realized and unrealized) - included in earnings - Financial expenses (income), net (46 ) Settlement by issuance shares (110 ) Balance as of December 31, 2014 $ -

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of composition of assets grouped by major classifications	Composition of assets, grouped by major classifications, is as follows: December 31, 2015 2014 ($ in thousands) Cost: Computer equipment $ 221 $ 242 Office furniture and equipment 104 110 Machinery and equipment 961 951 Leasehold improvements 143 194 1,429 1,497 Less - accumulated depreciation and amortization (957 ) (875 ) Net carrying amount $ 472 $ 622

LOAN (Tables)

LOAN (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of future principal payments obligation for the Loan	As of December 31, 2015, the future principal payments obligation for the Loan were as follows: ($ in thousands) Year Ended December 31: 2016 4,234 2017 776 $ 5,010

RELATED PARTIES TRANSACTIONS (T

RELATED PARTIES TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Schedule of balances with related parties	Balances with related parties: December 31, 2015 2014 ($ in thousands) Current liabilities: Other accounts payable $ 132 $ 241
Schedules of transactions with related parties	Transactions with related parties: Year ended December 31, 2015 2014 ($ in thousands) Total expenses $ 1,892 $ 3,269

COMMITMENTS AND CONTINGENT LI28

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of aggregate future minimum lease obligations for office rent under non-cancelable operating lease agreements	As of December 31, 2015, the aggregate future minimum lease obligations for office rent under non-cancelable operating lease agreements were as follows: ($ in thousands) Year Ended December 31: 2016 $ 320 2017 5 $ 325

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Schedule of warrants and share options	The following table summarizes information about warrants and share options to employees: Year ended December 31, 2015 2014 Number of warrants Weighted average exercise price Number of warrants Weighted average exercise price Outstanding - beginning of period 537,018 $ 40.10 368,818 $ 45.50 Granted 214,499 $ 5.31 184,652 $ 29.10 Forfeited (37,830 ) $ 30.68 (16,452 ) $ 39.00 Outstanding -end of period 713,687 $ 30.10 537,018 $ 40.10 Exercisable at the end of the period 344,787 $ 46.37 229,201 $ 54.80 The following table summarizes information about warrants and share options to non-employees: Year ended December 31, 2015 2014 Number of warrants and options Weighted average exercise price Number of warrants and options Weighted average exercise price Outstanding - beginning of period 139,902 $ 44.80 154,315 $ 45.70 Forfeited (5,608 ) $ 30.67 (14,413 ) $ 54.40 Outstanding - end of period 134,294 $ 45.37 139,902 $ 44.80 Exercisable at the end of the period 133,888 $ 45.36 139,140 $ 44.70
Schedule of information about restricted shares to employees	The following table summarizes information about restricted shares to employees: Year ended December 31, 2015 2014 Number of restricted shares Number of restricted shares Outstanding - beginning of period 103,016 54,654 Granted 196,178 65,076 Forfeited (10,145 ) (718 ) Vested (141,834 ) (15,996 ) Outstanding - end of period 147,215 103,016
Schedule of warrants and options outstanding and exercisable	The following table provides additional information about all warrants and options outstanding and exercisable: Outstanding as of December 31, 2015 Exercise price Warrants and options outstanding Weighted average remaining contractual life (years) Warrants and options exercisable $0-$8.3 251,637 8.19 38,709 $19.7-$29.8 227,249 7.80 117,081 $30.5-$34 87,202 7.67 43,065 $40.5-$49.285 93,283 5.78 91,210 $60-$78 172,360 2.92 172,360 $80-$100 16,250 5.42 16,250 847,981 6.64 478,675
Schedule of assumptions used in fair value of options granted to employees	The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the years ended December 31, 2015 and 2014: Year ended December 31, 2015 2014 Expected life 5-6.5 years 5.5-6.5 years Risk-free interest rates 1.41%-1.71 % 1.64%-2.18 % Volatility 62.68%-71.12 % 62.89%-68 % Dividend yield 0 % 0 %
Schedule of allocation of total share-based compensation expense	The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations: Year ended December 31, 2015 2014 ($ in thousands) Cost of revenues $ 8 $ 13 Research and development 716 534 Sales and marketing 179 446 General and administrative 2,145 3,145 Restructuring and impairment 59 $ 3,107 $ 4,138

TAXES ON INCOME (Tables)

TAXES ON INCOME (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of components of loss before income taxes	The components of loss before income taxes are as follows: Year ended December 31, 2015 2014 ($ in thousands) Profit (loss) before taxes on income: InspireMD, Inc. $ (6,131 ) $ (11,671 ) Subsidiaries (9,450 ) (13,412 ) $ (15,581 ) $ (25,083 )
Schedule of reconciliation of the theoretical tax expense	The following is a reconciliation of the theoretical tax expense, assuming all income was taxed at the regular tax rates applicable to the Company in the U.S. and the actual tax expense: Year ended December 31, 2015 2014 ($ in thousands) Loss before taxes on income, as reported in the statements of operations $ 15,581 $ 25,083 Theoretical tax benefit (5,297 ) (8,529 ) Decrease in tax benefit resulting from permanent differences 273 390 Increase (decrease) in taxes on income resulting from the computation of deferred taxes at a rate which is different from the theoretical rate, and other 716 2,038 Difference between income reported for tax purposes and income for financial reporting purposes — net 50 1,100 Decrease in theoretical tax benefit resulting from subsidiaries different tax rate (53 ) (73 ) Change in corporate tax rates - Change in valuation allowance 4,315 5,086 $ 4 $ 12
Schedule of changes in the valuation allowance	The changes in the valuation allowance for the year ended December 31, 2015 and 2014 were as follows: Year ended December 31, 2015 2014 ($ in thousands) Balance at the beginning of the year $ 24,655 $ 19,569 Changes during the year 4,451 5,086 Balance at the end of the year $ 29,106 $ 24,655
Schedule of open tax years by major jurisdiction	A summary of open tax years by major jurisdiction is presented below: Jurisdiction Years U.S. 2012-2015 Israel 2012-2015 Germany 2010-2015 United Kingdom 2014-2015
Schedule of deferred income tax	December 31, 2015 2014 ($ in thousands) Short-term: Allowance for doubtful accounts $ 74 $ 89 Provision for vacation and recreation pay 105 59 179 148 Long-term: R&D expenses 1,326 1,738 Share-based compensation 3,873 2,990 Carry forward tax losses 23,674 19,729 Accrued severance pay, net 54 50 28,927 24,507 Less-valuation allowance (29,106 ) (24,655 ) $ - $ -

SUPPLEMENTARY FINANCIAL STATE31

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
Schedule of allowance for doubtful accounts	The changes in “Allowance for doubtful accounts” during the years ended December 31, 2015 and 2014 are as follows: Year ended December 31, 2015 2014 ($ in thousands) Balance at beginning of period $ 337 $ 405 Additions during the period 72 35 Deductions during the period (49 ) (57 ) Exchange rate differences (14 ) (46 ) Balance at end of period 346 $ 337
Schedule of inventories	December 31, 2015 2014 ($ in thousands) Finished goods $ 301 $ 1,273 Work in process $ 307 326 Raw materials and supplies $ 145 325 $ 753 $ 1,924
Schedule of accounts payable and accruals-other	December 31, 2015 2014 ($ in thousands) Employees and employee institutions $ 412 $ 1,022 Accrued vacation and recreation pay 377 410 Accrued clinical trials expenses 582 1,016 Provision for sales commissions 80 120 Accrued expenses 552 993 Taxes payable 3 15 $ 2,006 $ 3,576

ENTITY WIDE DISCLOSURES (Tables

ENTITY WIDE DISCLOSURES (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of revenues are attributed to geographic areas	Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues by geographic areas: Year ended December 31, 2015 2014 ($ in thousands) Germany 519 286 Italy 415 96 Brazil 238 95 Belarus 226 285 Middle East 94 792 Other 818 1,264 2,310 $ 2,818
Schedule of revenues are attributed to geographic areas by product	By product: Year ended December 31, 2015 2014 ($ in thousands) MGuard* 1,607 2,797 CGuard 703 21 2,310 $ 2,818 *Includes revenue from sales of both MGuard Prime and MGuard.
Schedule of revenues are attributed to geographic areas principal customers	By principal customers: Year ended December 31, 2015 2014 Customer A 11 % 7 % Customer B 10 % 10 % Customer C 21 %

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Details Narrative)	Oct. 01, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reserve stock split ratio	0.1

SIGNIFICANT ACCOUNTING POLICI34

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)Numbershares	Dec. 31, 2014USD ($)shares
Description of uncertain tax benefits	Tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
Advertising expense | $	$ 200	$ 800
Number of antidilutive securities excluded from computation of earnings per share amount | shares	5,004,836	1,352,326
Number of operating segement	1
Number of reportable segement	1
Machinery and Equipment [Member]
Estimated useful life	7 years
Computers And Electronic Equipment [Member]
Description of methodology used for computing depreciation	Straight-line method.
Computers And Electronic Equipment [Member] | Minimum [Member]
Estimated useful life	3 years
Office Furniture And Equipment [Member] | Minimum [Member]
Estimated useful life	7 years
Office Furniture And Equipment [Member] | Maximum [Member]
Estimated useful life		15 years

RESTRUCTURING AND IMPAIRMENT (D

RESTRUCTURING AND IMPAIRMENT (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 305	[1]
Lease settlement	101	[2]
Total restructuring	406
Impairment of royalties buyout	576	[3]
Total restructuring and impairment	$ 982
[1]	During the year ended December 31, 2015, the company incurred $305,000 of costs associated with reducing the Company's headcount.
[2]	On November 5, 2015, the Company entered into a second amendment (the "Second Lease Amendment") to the lease agreement for its facilities in the U.S. Pursuant to the Second Lease Amendment and effective January 1, 2016, the Company agreed to reduce its leased space and surrender the released premises. The Company also agreed to pay transaction costs and settlement amount of $101,000.
[3]	During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents.

FAIR VALUE MEASURMENT (Details)

FAIR VALUE MEASURMENT (Details) - Fair Value Inputs Level 3 [Member] - Anti-Dilution Rights [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning	$ 156
Total losses (gains) (realized and unrealized) - included in earnings - Financial expenses (income), net	(46)
Settlement by issuance shares	$ (110)
Balance at ending

PROPERTY, PLANT AND EQUIPMENT37

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Gross	$ 1,429	$ 1,497
Less - accumulated depreciation and amortization	(957)	(875)
Net carrying amount	472	622
Computers And Electronic Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross	221	242
Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross	104	110
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross	961	951
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross	$ 143	$ 194

PROPERTY, PLANT AND EQUIPMENT38

PROPERTY, PLANT AND EQUIPMENT (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 152	$ 163

LIABILITY FOR EMPLOYEES RIGHT39

LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT (Details Narrative) - Israeli Severance Compensation [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Percentage of monthly salaries	8.33%
Severance expenses	$ 211	$ 233
Defined contribution plan expense	213	$ 285
Defined contribution plan expense estimated	$ 165

LOAN (Details)

LOAN (Details) $ in Thousands	Dec. 31, 2015USD ($)
Debt Disclosure [Abstract]
2,016	$ 4,234
2,017	776
Total	$ 5,010

LOAN (Details Narrative)

LOAN (Details Narrative) - 2013 Security and Loan Agreement [Member] - Term Loan [Member] $ in Thousands	Oct. 23, 2013USD ($)
Short-term Debt [Line Items]
Original aggregate principal amount	$ 10,000
Description of interesr rate	The annual interest rate on the Loan is prime plus 4%.
Minimum interest rate	10.50%
Description of repayment terms	The Company is permitted to prepay all or a portion of the Loan. However, any prepayments of the Loan will be subject to a penalty of (i) 2%, if the prepayment occurs within 12 months of the Loan being requested by the Company and InspireMD Ltd. (the “Advance Date”), (ii) 1%, if the prepayment occurs between 12 and 24 months after the Advance Date, and (iii) 0.5%, if the prepayment occurs more than 24 months after the Advance Date.
Unused borrowing capacity fee	$ 500

RELATED PARTIES TRANSACTIONS (D

RELATED PARTIES TRANSACTIONS (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current liabilities:
Other accounts payable	$ 132	$ 241

RELATED PARTIES TRANSACTIONS 43

RELATED PARTIES TRANSACTIONS (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Total expenses	$ 1,892	$ 3,269

RELATED PARTIES TRANSACTIONS 44

RELATED PARTIES TRANSACTIONS (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jun. 29, 2015	Jan. 26, 2015	Jan. 05, 2015	Jan. 29, 2014	Dec. 31, 2015	Dec. 31, 2014	Jul. 31, 2015	Jan. 28, 2015
Related Party Transaction [Line Items]
Tax withholding obligations amount					$ 113	$ 115
Mr. Alan Milinazzo [Member]
Related Party Transaction [Line Items]
Number of option granted		30,777		8,633		39,968
Exercise price (in dollars per share)		$ 7.2
Fair value of option		$ 131				$ 736
Liability fair value					84
Non cash annual salary compensation expense					$ 84
Number of shares upon tax withholding obligations					32,811	4,569
Tax withholding obligations amount					$ 81	$ 115
Percentage of additional grant awards					0.50%
Number of additional option granted		5,300
Annual bonus							$ 45,833	$ 69,105
Mr. Alan Milinazzo [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Exercise price (in dollars per share)						$ 29.70
Mr. Alan Milinazzo [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Exercise price (in dollars per share)						$ 31
Mr. Alan Milinazzo [Member] | Second Amdedment Employment Agreement [Member]
Related Party Transaction [Line Items]
Percentage of base salary			50.00%
Mr. Alan Milinazzo [Member] | Third Amdedment Employment Agreement [Member]
Related Party Transaction [Line Items]
Transaction amounts	$ 5
Mr. Alan Milinazzo [Member] | Restricted Stock [Member]
Related Party Transaction [Line Items]
Number of equity award granted		20,509		8,633		18,273
Description of vesting rights		Vest in three equal annual installments.				Vest in three equal annual installments
Fair value of equity award						$ 554
Number of additional equity award granted		5,300
Mr. Alan Milinazzo [Member] | Restricted Stock [Member] | Second Amdedment Employment Agreement [Member]
Related Party Transaction [Line Items]
Number of equity award granted		31,250
Fair value of equity award		$ 225
Requisite service period		1 year
Mr. Alan Milinazzo [Member] | Restricted Stock [Member] | Third Amdedment Employment Agreement [Member]
Related Party Transaction [Line Items]
Number of equity award granted					63,825
Director [Member]
Related Party Transaction [Line Items]
Number of option granted					30,797	33,500
Exercise price (in dollars per share)						$ 31
Fair value of option					$ 338	$ 636
Description of vesting rights					Three-year vesting period with one-third of such awards vesting each year.	Three-year vesting period with one-third of such awards vesting each year.
Vesting period					3 years	3 years
Number of share issued upon lieu of cash compensation					107,744
Director [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Exercise price (in dollars per share)					$ 1.7
Director [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Exercise price (in dollars per share)					$ 7.8

COMMITMENTS AND CONTINGENT LI45

COMMITMENTS AND CONTINGENT LIABILITIES (Details) $ in Thousands	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 320
2,017	5
Total	$ 325

COMMITMENTS AND CONTINGENT LI46

COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) - USD ($) $ in Thousands	Dec. 13, 2013	Aug. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2011
Gain Contingencies [Line Items]
Rent expense			$ 383	$ 388
Restructuring and impairment charges			101
Future minimum lease obligations			325
Lease Agreement [Member] | Israel [Member]
Gain Contingencies [Line Items]
Lease term					2 years
Lease arrangements, renewal term					4 years
Lease Agreement [Member] | US [Member]
Gain Contingencies [Line Items]
Lease term	3 years
First Amendment Lease Agreement [Member] | Motor vehicles [Member]
Gain Contingencies [Line Items]
Future minimum lease obligations			$ 6
First Amendment Lease Agreement [Member] | US [Member]
Gain Contingencies [Line Items]
Lease arrangements, renewal term		4 years

COMMITMENTS AND CONTINGENT LI47

COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative 1) - USD ($) $ in Thousands		Jul. 01, 2015	Aug. 22, 2013	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2015
Gain Contingencies [Line Items]
Impairment of royalties buyout	[1]			$ 576
Amendment License Agreement [Member] | MGuard PrimeTM [Member]
Gain Contingencies [Line Items]
Percentage of royalty fees		2.90%	2.90%
Advance royalty payment						$ 192
Percentage of royalty fee aggregate net sales up to $10,560,000						2.00%
Percentage of royalty fee aggregate net sales after $10,560,000						2.50%
Impairment of royalties buyout				576
Royalty expense				$ 149	$ 148
[1]	During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents.

COMMITMENT AND CONTINGENT LIABI

COMMITMENT AND CONTINGENT LIABILITIES (Details Narrative 2) - USD ($) $ / shares in Units, $ in Thousands	May. 27, 2015	Nov. 30, 2015	May. 31, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2012	Jul. 31, 2012	Dec. 31, 2015
Declaratory and Enforcement Order [Member] | InspireMD GmbH [Member]
Description of action taken by court					The court accepted a motion to dismiss the former CEO and president from the lawsuit.
Declaratory and Enforcement Order [Member] | Former CEO & President [Member]
Number of options granted	5,855						8,364
Exercise prices (in dollars per share)							$ 7.60
Description of action taken by plaintiff	Waived his entire claim against the Company, in consideration of the Company's consent to allow him to exercise 5,855 options of the Company's shares of common stock.
Former Service Provider [Member] | InspireMD GmbH [Member]
Description of action taken by court				The interest rate made by the Court of Appeal in Argentina was increased retroactively.
Description of domicile of litigation						Labor Court in Buenos Aires, Argentina
Maximum amount of claim						$ 193,378
Percentage of social benefits & legal expenses of awards						25.00%
Litigation provision				$ 340		$ 250		$ 100
Litigation expense			$ 20
Settlement amount			$ 80
Increase decrease in loss contingency provision				$ 90				240
Payment for legal proceedings		$ 1,965
Former Service Provider [Member] | InspireMD GmbH [Member] | Euro [Member]
Maximum amount of claim								$ 1,075
Former Service Provider [Member] | InspireMD GmbH [Member] | Argentina Pesos Interest Rate [Member]
Percentage of interest rate						18.50%
Former Service Provider [Member] | InspireMD GmbH [Member] | USA Dollar Interest Rate [Member]
Percentage of interest rate						6.00%

EQUITY (Details)

EQUITY (Details) - Warrants and Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Outstanding [Roll Forward]
Outstanding - beginning of period	537,018	368,818
Granted	214,499	184,652
Forfeited	(37,830)	(16,452)
Outstanding - end of period	713,687	537,018
Exercisable at the end of the period	344,787	229,201
Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Exercise Price [Roll Forward]
Outstanding - beginning of period	$ 40.10	$ 45.50
Granted	5.31	29.10
Forfeited	30.68	39
Outstanding - end of period	30.10	40.10
Exercisable at the end of the period	$ 46.37	$ 54.80
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Outstanding [Roll Forward]
Outstanding - beginning of period	139,902	154,315
Forfeited	(5,608)	(14,413)
Outstanding - end of period	134,294	139,902
Exercisable at the end of the period	133,888	139,140
Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Exercise Price [Roll Forward]
Outstanding - beginning of period	$ 44.80	$ 45.70
Forfeited	30.67	54.40
Outstanding - end of period	45.37	44.80
Exercisable at the end of the period	$ 45.36	$ 44.70

EQUITY (Details 1)

EQUITY (Details 1) - Restricted Stock [Member] - Employees [Member] - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding - beginning of period	103,016	54,654
Granted	196,178	65,076
Forfeited	(10,145)	(718)
Vested	(141,834)	(15,996)
Outstanding - end of period	147,215	103,016

EQUITY (Details 2)

EQUITY (Details 2)	12 Months Ended
	Dec. 31, 2015shares
Share-based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Option and Other Than Option [Roll Forward]
Outstanding	847,981
Weighted average remaining contractual life	6 years 7 months 24 days
Exercisable	478,675
Warrants and Options [Member] | Exercise Price $0-$8.3 [Member]
Share-based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Option and Other Than Option [Roll Forward]
Outstanding	251,637
Weighted average remaining contractual life	8 years 2 months 8 days
Exercisable	38,709
Warrants and Options [Member] | Exercise Price $19.7-$29.8 [Member]
Share-based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Option and Other Than Option [Roll Forward]
Outstanding	227,249
Weighted average remaining contractual life	7 years 9 months 18 days
Exercisable	117,081
Warrants and Options [Member] | Exercise Price $30.5-$34 [Member]
Share-based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Option and Other Than Option [Roll Forward]
Outstanding	87,202
Weighted average remaining contractual life	7 years 8 months 1 day
Exercisable	43,065
Warrants and Options [Member] | Exercise Price $40.5-$49.285 [Member]
Share-based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Option and Other Than Option [Roll Forward]
Outstanding	93,283
Weighted average remaining contractual life	5 years 9 months 11 days
Exercisable	91,210
Warrants and Options [Member] | Exercise Price $60-$78 [Member]
Share-based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Option and Other Than Option [Roll Forward]
Outstanding	172,360
Weighted average remaining contractual life	2 years 11 months 1 day
Exercisable	172,360
Warrants and Options [Member] | Exercise Price $80-$100 [Member]
Share-based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Option and Other Than Option [Roll Forward]
Outstanding	16,250
Weighted average remaining contractual life	5 years 5 months 1 day
Exercisable	16,250

EQUITY (Details 3)

EQUITY (Details 3) - Employees [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Dividend yield	0.00%	0.00%
Maximum [Member]
Class of Stock [Line Items]
Expected life	6 years 6 months	6 years 6 months
Risk-free interest rates	1.71%	2.18%
Volatility	71.12%	68.00%
Minimum [Member]
Class of Stock [Line Items]
Expected life	5 years	5 years 6 months
Risk-free interest rates	1.41%	1.64%
Volatility	62.68%	62.89%

EQUITY (Details 4)

EQUITY (Details 4) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Total share-based compensation expense	$ 3,107	$ 4,138
Cost of Revenues [Member]
Class of Stock [Line Items]
Total share-based compensation expense	8	13
Research And Development [Member]
Class of Stock [Line Items]
Total share-based compensation expense	716	534
Selling And Marketing [Member]
Class of Stock [Line Items]
Total share-based compensation expense	179	446
General And Administrative Expense [Member]
Class of Stock [Line Items]
Total share-based compensation expense	2,145	$ 3,145
Restructuring And impairment [Member]
Class of Stock [Line Items]
Total share-based compensation expense	$ 59

EQUITY (Details Narrative)

EQUITY (Details Narrative) $ / shares in Units, $ in Thousands	Oct. 01, 2015shares	Mar. 09, 2015USD ($)$ / sharesshares	Nov. 07, 2014USD ($)$ / sharesshares	Aug. 15, 2014USD ($)shares	Oct. 23, 2013USD ($)	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Sep. 30, 2015$ / sharesshares
Class of Stock [Line Items]
Reserve stock spilit ratio	0.1
Common stock, par value (in dollars per share) | $ / shares						$ 0.0001	$ 0.0001	$ 0.0001
Common stock & restricted shares, issued	7,800					7,676,074	4,136,852	78,000
Common stock & restricted shares, outstanding	7,800					7,676,074	4,136,852	78,000
Common stock, authorized	50,000					50,000,000	50,000,000	125,000
Value of shares issued upon new issue | $						$ 12,432	$ 9,645
Maximum aggregate offering price | $						$ 12,432	$ 9,535
2011 Share Purchase Agreement [Member]
Class of Stock [Line Items]
Number of shares issued upon acquistion							84,289
At-The-Market Sales Agreement [Member] | MLV & Co. LLC [Member]
Class of Stock [Line Items]
Number of shares issued upon new issue				94,800
Value of shares issued upon new issue | $				$ 2,200
Maximum aggregate offering price | $					$ 40,000
Sales commission percent					3.00%
Capital Stock [Member]
Class of Stock [Line Items]
Common stock, par value (in dollars per share) | $ / shares						$ 0.0001
Common stock, authorized						55,000,000
Blank Check Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized						5,000,000
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued upon new issue						3,436,968	725,927
Value of shares issued upon new issue | $						$ 1
Common Stock [Member] | 2014 Registered Direct Offering [Member]
Class of Stock [Line Items]
Number of shares issued upon new issue		3,436,968	626,189
Share price (in dollars per share) | $ / shares			$ 13
Net proceeds from issuance of private offering | $		$ 12,400	$ 7,400
Warrant [Member] | 2014 Registered Direct Offering [Member]
Class of Stock [Line Items]
Number of warrants called		3,436,968	313,100
Number of warrants called by each purchaser		1	0.5
Warrant term		5 years	42 months
Warrant exercise price (in dollars per share) | $ / shares		$ 5.50	$ 17.5

EQUITY (Details Narrative 1)

EQUITY (Details Narrative 1) - USD ($) $ / shares in Units, $ in Thousands	Mar. 28, 2011	Dec. 31, 2015	Dec. 31, 2014	Sep. 09, 2015	Dec. 16, 2013
Class of Stock [Line Items]
Unrecognized compensation cost		$ 17,500
Unrecognized compensation cost, period		9 months 25 days
Warrant & Option [Member]
Class of Stock [Line Items]
Weighted average remaining contractual life, vested and exercisable		5 years 14 days
Aggregate intrinsic value, exercisable		$ 25,563
Weighted average fair value		$ 3.11	$ 17.80
CEO, Employees & Directors [Member]
Class of Stock [Line Items]
Number of option granted		214,499	184,652
Fair value of option		$ 660	$ 3,279
Number of option vested		107,744
Description of vesting rights		107,744 options are fully vested as of their grant date and the remaining options are subject to a three-year vesting period with one-third of such awards vesting each year.	Three-year vesting period with one-third of such awards vesting each year.
Vesting period		3 years
CEO, Employees & Directors [Member] | Restricted Stock [Member]
Class of Stock [Line Items]
Description of vesting rights		43,300 restricted shares are subject to a one-year vesting period, 9,250 restricted shares are fully vested as of their grant date and are subject to a 6 month lock up period, 63,825 restricted shares are fully vested as of their grant date, 32,914 restricted shares are subject to a six-month vesting period and 46,889 restricted shares are subject to a three-year vesting period, with one-third of such awards vesting each year.	Three-year vesting period with one-third of such awards vesting each year.
Number of equity award granted		196,178	65,076
Fair value of equity award		$ 1,157	$ 1,916
Vesting period			3 years
CEO, Employees & Directors [Member] | Restricted Stock [Member] | Vesting Tranch One [Member]
Class of Stock [Line Items]
Number of equity award vested		43,300
Vesting period		1 year
CEO, Employees & Directors [Member] | Restricted Stock [Member] | Vesting Tranch Two [Member]
Class of Stock [Line Items]
Number of equity award vested		9,250
Vesting period		6 months
CEO, Employees & Directors [Member] | Restricted Stock [Member] | Vesting Tranch Three [Member]
Class of Stock [Line Items]
Number of equity award vested		63,825
CEO, Employees & Directors [Member] | Restricted Stock [Member] | Vesting Tranch Four [Member]
Class of Stock [Line Items]
Number of equity award vested		32,914
Vesting period		6 months
CEO, Employees & Directors [Member] | Restricted Stock [Member] | Vesting Tranch Five [Member]
Class of Stock [Line Items]
Number of equity award vested		46,889
Vesting period		3 years
CEO, Employees & Directors [Member] | Minimum [Member]
Class of Stock [Line Items]
Exercise price (in dollars per share)		$ 1.70	$ 11.40
CEO, Employees & Directors [Member] | Maximum [Member]
Class of Stock [Line Items]
Exercise price (in dollars per share)		$ 8.30	$ 32.30
Mr. James J. Barry [Member]
Class of Stock [Line Items]
Number of option granted			45,001
Mr. James J. Barry [Member] | Restricted Stock [Member]
Class of Stock [Line Items]
Number of equity award granted			15,000
2011 Umbrella Option Plan [Member]
Class of Stock [Line Items]
Expiration date	Mar. 27, 2021
Number of shares reserve for future issuance	500,000	18,603
2013 Long-Term Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares reserve for future issuance		439,930		970,000	500,000

TAXES ON INCOME (Details)

TAXES ON INCOME (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Profit (loss) before taxes on income:
Loss before income taxes	$ (15,581)	$ (25,083)
InspireMD, Inc. [Member]
Profit (loss) before taxes on income:
Loss before income taxes	(6,131)	(11,671)
SubsidiariesMember
Profit (loss) before taxes on income:
Loss before income taxes	$ (9,450)	$ (13,412)

TAXES ON INCOME (Details 1)

TAXES ON INCOME (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Loss before taxes on income, as reported in the statements of operations	$ 15,581	$ 25,083
Theoretical tax benefit	(5,297)	(8,529)
Decrease in tax benefit resulting from permanent differences	273	390
Increase (decrease) in taxes on income resulting from the computation of deferred taxes at a rate which is different from the theoretical rate, and other	716	2,038
Difference between income reported for tax purposes and income for financial reporting purposes - net	50	1,100
Decrease in theoretical tax benefit resulting from subsidiaries different tax rate	(53)	$ (73)
Change in corporate tax rates
Change in valuation allowance	4,315	$ 5,086
Income tax expense	$ 4	$ 12

TAXES ON INCOME (Details 2)

TAXES ON INCOME (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Deferred Tax Assets, Valuation Allowance [Roll Forward]
Balance at the beginning of the year	$ 24,655	$ 19,569
Changes during the year	(4,315)	(5,086)
Balance at the end of the year	$ 29,106	$ 24,655

TAXES ON INCOME (Details 3)

TAXES ON INCOME (Details 3)	12 Months Ended
	Dec. 31, 2015
Internal Revenue Service (IRS) [Member] | Earliest Tax Year [Member]
Open Tax Year	2,012
Internal Revenue Service (IRS) [Member] | Latest Tax Year [Member]
Open Tax Year	2,015
Israel Tax Authority [Member] | Earliest Tax Year [Member]
Open Tax Year	2,012
Israel Tax Authority [Member] | Latest Tax Year [Member]
Open Tax Year	2,015
Federal Ministry Of Finance Germany [Member] | Earliest Tax Year [Member]
Open Tax Year	2,010
Federal Ministry Of Finance Germany [Member] | Latest Tax Year [Member]
Open Tax Year	2,015
Her Majesty's Revenue and Customs (HMRC) [Member] | Earliest Tax Year [Member]
Open Tax Year	2,014
Her Majesty's Revenue and Customs (HMRC) [Member] | Latest Tax Year [Member]
Open Tax Year	2,015

TAXES ON INCOME (Details 4)

TAXES ON INCOME (Details 4) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Short-term:
Allowance for doubtful accounts	$ 74	$ 89
Provision for vacation and recreation pay	105	59
Total short-term:	179	148
Long-term:
R&D expenses	1,326	1,738
Share-based compensation	3,873	2,990
Carry forward tax losses	23,674	19,729
Accrued severance pay, net	54	50
Deferred tax assets noncurrent	28,927	24,507
Less-valuation allowance	$ (29,106)	$ (24,655)	$ (19,569)
Total long-term:

TAXES ON INCOME (Details Narrat

TAXES ON INCOME (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Net carry forward tax loss	$ 52,000
Israel Tax Authority [Member] | InspireMD Ltd [Member
Corporate tax rate	26.50%
Description of income tax hoilday	Certain conditions stipulated by the above law, is a two-year exemption and five years of a reduced tax rate of 25% from tax on income derived from beneficiary activities in facilities in Israel. The two-year exemption starts only when the Company starts to pay taxes after using all carryforward tax losses. The tax benefit period is twelve years from the year of election, which means that after a year of election, the two-year exemption and five years of reduced tax rate can only e used within the next twelve years. The Company elected the year 2007, as a year of election and 2011 as an additional year of election.
Tax rate on income of beneficiary enterprises	15.00%
Tax exemption period	2 years
Net carry forward tax loss	$ 29,000
Israel Tax Authority [Member] | InspireMD Ltd [Member | Other Than Development Zone A [Member]
Tax rate on income of preferred enterprises	12.00%
Revised tax rate on income of preferred enterprises	16.00%
Federal Ministry Of Finance Germany [Member] | InspireMD GmbH [Member]
Corporate tax rate	15.825%
Corporate trade tax rate	17.15%
Her Majesty's Revenue and Customs (HMRC) [Member] | InspireMD UK [Member]
Corporate tax rate	20.00%

SUPPLEMENTARY FINANCIAL STATE62

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance at beginning of period	$ 337	$ 405
Additions during the period	72	35
Deductions during the period	(49)	(57)
Exchange rate differences	(14)	(46)
Balance at end of period	$ 346	$ 337

SUPPLEMENTARY FINANCIAL STATE63

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details 1) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Finished goods	$ 301	$ 1,273
Work in process	307	326
Raw materials and supplies	145	325
Total inventories	$ 753	$ 1,924

SUPPLEMENTARY FINANCIAL STATE64

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details 2) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Employees and employee institutions	$ 412	$ 1,022
Accrued vacation and recreation pay	377	410
Accrued clinical trials expenses	582	1,016
Provision for sales commissions	80	120
Accrued expenses	552	993
Taxes payable	3	15
Total accounts payable and accruals other	$ 2,006	$ 3,576

ENTITY WIDE DISCLOSURES (Detail

ENTITY WIDE DISCLOSURES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenues	$ 2,310	$ 2,818
Germany [Member]
Revenues	519	286
Italy [Member]
Revenues	415	96
Brazil [Member]
Revenues	238	95
Belarus [Member]
Revenues	226	285
Middle East [Member]
Revenues	94	792
Other [Member]
Revenues	$ 818	$ 1,264

ENTITY WIDE DISCLOSURES (Deta66

ENTITY WIDE DISCLOSURES (Details 1) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenues		$ 2,310	$ 2,818
Sales [Member]
Segment Reporting Information [Line Items]
Revenues		2,310	2,818
Sales [Member] | MGuard [Member]
Segment Reporting Information [Line Items]
Revenues	[1]	1,607	2,797
Sales [Member] | Cguard [Member]
Segment Reporting Information [Line Items]
Revenues		$ 703	$ 21
[1]	Includes revenue from sales of both MGuard Prime and MGuard.

ENTITY WIDE DISCLOSURES (Deta67

ENTITY WIDE DISCLOSURES (Details 2) - Sales [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Customer A [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	11.00%	7.00%
Customer B [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	10.00%	10.00%
Customer C [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer		21.00%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Mar. 21, 2016	Jan. 26, 2016	Jan. 21, 2016	Jan. 16, 2016	Jan. 26, 2015	Jan. 29, 2014	Dec. 31, 2014
Mr. Alan Milinazzo [Member]
Subsequent Event [Line Items]
Number of option granted					30,777	8,633	39,968
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from sale of securities	$ 1,400,000
Subsequent Event [Member] | Underwritten Public Offering [Member]
Subsequent Event [Line Items]
Number of common shares sold	1,900,000
Share price (in dollars per share)	$ 0.59
Subsequent Event [Member] | Underwritten Public Offering [Member] | Warrant [Member]
Subsequent Event [Line Items]
Number of common shares purchased	950,000
Warrant terms	5 years
Exercise price	$ 0.59
Proceeds from sale of securities	$ 1,100,000
Description of warrant	One half of one share of common stock for each share of common stock.
Subsequent Event [Member] | Underwritten Private Offering [Member]
Subsequent Event [Line Items]
Number of common shares sold	1,033,051
Share price (in dollars per share)	$ 0.59
Subsequent Event [Member] | Underwritten Private Offering [Member] | Warrant [Member]
Subsequent Event [Line Items]
Number of common shares purchased	516,526
Warrant terms	5 years
Exercise price	$ 0.59
Proceeds from sale of securities	$ 600,000
Description of warrant	One half of one share of common stock for each share of common stock.
Subsequent Event [Member] | Mr. Alan Milinazzo [Member] | Fourth Amendment Employment Agreement [Member]
Subsequent Event [Line Items]
Monthly salaries and related expenses			$ 18,750,000
Subsequent Event [Member] | Optionholders [Member]
Subsequent Event [Line Items]
Number of option cancelled		422,443
Subsequent Event [Member] | Maximum [Member] | Mr. Isaac Blech [Member]
Subsequent Event [Line Items]
Number of option granted				780,000
Number of option vested				195,000
Description of vesting rights				(i) the Company raising at least $15 million through an equity offering; (ii) the Company ’s market cap becoming equal to or greater than $25 million; (iii) the Company receiving research coverage by three new analysts at a leading investment bank; or (iv) the tripling of the Company’s market cap from the date of appointment. Any of the foregoing conditions, if achieved following the director’s appointment but prior to April 30, 2016, will be deemed satisfied on the date of grant. However, in the event (i) of the director’s death or permanent disability, (ii) a change in control (as defined in the Plan) or (iii) if the director is asked to resign for any reason other than cause (as defined in the Company’s form of Nonqualified Stock Option Agreement under its Plan), the options shall vest immediately in full.
Expiration period				10 years
Subsequent Event [Member] | Maximum [Member] | Optionholders [Member]
Subsequent Event [Line Items]
Exercise price for option cancelled (in dollars per share)		$ 100
Subsequent Event [Member] | Minimum [Member] | Optionholders [Member]
Subsequent Event [Line Items]
Exercise price for option cancelled (in dollars per share)		$ 7.20